Program Overview
This CME activity will discuss recent advances in the treatment and management of patients with pulmonary arterial hypertension (PAH). The expert faculty will provide learners with a scientific update regarding current evidence-based guidelines and appropriate diagnostic strategies. Recent clinical trial data of new and emerging therapeutic options for the treatment of PAH will be reviewed. The faculty will also discuss how to develop effective treatment strategies to improve outcomes and he overall quality of life for PAH patients. At the conclusion of the education program, clinicians will be better acquainted with the treatment and management of patients with PAH, ultimately improving patient outcomes.
Target Audience
Cardiologists, pulmonologists, primary care physicians, internists, nurse practitioners, nurses, and other healthcare providers involved in the management of patients with PAH.
Learning Objectives
- Distinguish current evidence-‐based guidelines for an accurate and early diagnosis of PAH
- Analyze clinical trial data of new and emerging therapeutic options for the treatment of PAH
- Develop effective treatment strategies to improve outcomes and the overall quality of life for patients with PAH for the healthcare team
Faculty
Aaron B. Waxman, MD, PhD
Pulmonary and Critical Care Medicine
Director, Pulmonary Vascular Disease Program
Executive Director, Center for Pulmonary-Heart Diseases
Brigham and Women’s Hospital Heart and Vascular Center
Associate Professor of Medicine, Harvard Medical School
Boston, MA
Evelyn M. Horn, MD
Director, Heart Failure and Pulmonary Hypertension
Perkin Heart Failure Center
Weill Cornell Medicine
New York, NY
—
Inderjit Singh, MBChB, BMedSci, MRCP
Director, Pulmonary Vascular Program
Pulmonary, Critical Care & Sleep Medicine
Yale School of Medicine
New Haven, CT
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
| Faculty | Relationship Identified With: |
| Aaron B. Waxman, MD, PhD | Consultant/Advisor: Acceleron Pharma, Inc.; Medtronic; United Therapeutics Corporation |
| Evelyn M. Horn, MD | Nothing to disclose |
| Inderjit Singh, MBChB, BMedSci, MRCP | Nothing to disclose |
Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Emma Boring; Chelsey Benedek and Kim Cheramie, MSN, RN-BC hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Financial Support
This activity has been supported by an independent educational grant from Actelion Pharmaceuticals US, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Actelion Pharmaceuticals US, Inc. do not recommend the use of any agent outside of the labeled indications.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
2. Complete the Pre-Activity Questions
3. Read or Review the activity content.
4. Complete the Post-Activity Test Questions and Evaluation.
5. Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
CE Inquiries/Special Needs
For all CME inquiries or special needs, please contact [email protected].
